Korro Bio, Inc. (KRRO) · Nov 5, 2026 · Earnings
Beat — EPS $(0.98) vs ~$1.26 consensus
Korro Bio’s third-quarter earnings beat on EPS as KRRO-121 entered Phase 1/2, but paused Novo revenue disappeared and clinical proof remains ahead.
Korro is a clinical-stage RNA-editing biotech moving from preclinical validation toward human testing, with KRRO-121 for hyperammonemia now entering Phase 1/2 and KRRO-111 for AATD being prepared for the clinic. Earlier company plans pointed to a KRRO-121 regulatory filing in the second half of 2026 and a cash runway into the second half of 2028.
The main business milestone arrived: KRRO-121 is now in people. Korro dosed the first healthy-volunteer cohort in ANCHOR, which moves the lead program beyond preclinical work; however, the meaningful efficacy test is still ahead because UCD patients are not expected to begin dosing until the first half of 2027. The filing says, “Dosed the first cohort in ANCHOR (AssessmeNt of Control of Hyperammonemia through Oligonucleotide-based RNA editing), the global Phase 1/2 clinical trial program for KRRO-121 in healthy volunteers and participants with UCD (NCT07773246).” 〔0〕
KRRO-111 also strengthens the platform story, but only at the animal-data stage. More than 95% SERPINA1 editing, roughly 93% functional M-AAT in circulation, and near-complete removal of pathogenic liver Z-AAT are impressive preclinical signals, supporting the planned regulatory submission in the first half of 2027. They do not yet establish safety, durability, or clinical benefit in humans. The filing reports, “KRRO-111 was administered to NSG PiZZ mice and achieved >95% editing of the SERPINA1 transcripts.” 〔1〕
The quarterly numbers beat the limited earnings bar, but the revenue line is structurally weaker. EPS was better than the published consensus, while revenue missed because the Novo Nordisk collaboration remained paused; that revenue loss was already largely understood from the prior disclosure, so it is not a new deterioration in the operating programs. The cost base also declined year over year, and the company maintained its previously established runway into the second half of 2028.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss per share (Income Statement) | $(0.98) | $(1.92) | $(1.26) |
| Collaboration revenue (Income Statement) | $0 | $1.09M | $0.19M |
| R&D expenses (Income Statement) | $12.1M | $13.8M | |
| Net loss (Income Statement) | $17.5M | $18.1M | |
| Cash and marketable securities (Balance Sheet) | $124.8M |
The cash position reduces near-term financing pressure, not development risk. Korro ended the quarter with $124.8 million and says that supports operations into the second half of 2028, giving it time to reach the planned UCD dosing, interim ANCHOR data, and KRRO-111 regulatory submission. The filing states, “Korro expects its cash, cash equivalents and marketable securities as of September 30, 2026 will fund operating expenses and capital expenditure requirements into the second half of 2028.” 〔2〕
Bottom line: This was a modest execution step forward: the lead program has entered human testing, the AATD program has compelling preclinical data, and cash lasts through the next major milestones. The positive clinical progress outweighs the revenue miss, but the core thesis still depends on future patient data rather than results delivered in this filing.
UCD dosing in ANCHOR, first half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!